Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 662
- Registration Number
- NCT05933044
- Locations
- 🇨🇦
Queen Elizabeth (QE) II Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT05924880
- Locations
- 🇨🇳
Research Site, Xiamen, China
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT05925530
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05911308
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Hirva Mamdani
- Target Recruit Count
- 38
- Registration Number
- NCT05903092
- Locations
- 🇺🇸
Karmanos Cancer Center (Wayne State University), Detroit, Michigan, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Target Recruit Count
- 40
- Registration Number
- NCT05886439
- Locations
- 🇨🇳
Cancer hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT05883644
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05848843
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 112
- Registration Number
- NCT05845450
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 25
- Registration Number
- NCT05809869
- Locations
- 🇭🇰
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.